Ewa LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 739 shares of the company’s stock after purchasing an additional 38 shares during the quarter. Ewa LLC’s holdings in Eli Lilly and Company were worth $347,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Eli Lilly and Company by 533,336.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 19,059,681 shares of the company’s stock valued at $8,938,609,000 after acquiring an additional 19,056,108 shares in the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $3,416,206,000. Moneta Group Investment Advisors LLC grew its stake in Eli Lilly and Company by 102,752.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after buying an additional 5,440,731 shares in the last quarter. Morgan Stanley increased its holdings in shares of Eli Lilly and Company by 44.1% in the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its position in shares of Eli Lilly and Company by 316.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,434,073 shares of the company’s stock valued at $217,569,000 after buying an additional 1,850,187 shares in the last quarter. 81.38% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, CAO Donald A. Zakrowski sold 670 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $571.10, for a total transaction of $382,637.00. Following the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total value of $130,169,600.00. Following the sale, the insider now directly owns 99,768,810 shares in the company, valued at approximately $60,404,028,326.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 535,538 shares of company stock valued at $20,881,299,452. Corporate insiders own 0.13% of the company’s stock.
Eli Lilly and Company Stock Up 2.0 %
Eli Lilly and Company Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a $1.13 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $4.52 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 81.88%.
Analysts Set New Price Targets
A number of research analysts recently commented on the company. Royal Bank of Canada increased their target price on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Citigroup boosted their target price on Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Bank of America increased their price target on shares of Eli Lilly and Company from $600.00 to $700.00 in a research report on Friday, October 6th. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $615.00 to $650.00 and gave the stock an “overweight” rating in a report on Monday, October 9th. Finally, Barclays lifted their target price on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $557.00.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Five stocks we like better than Eli Lilly and Company
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Target these 3 hot retail stocks for Black Friday deals
- Large Cap Stock Definition and How to Invest
- Cisco stock plummets on weak forecast: Is it a warning for tech?
- What Makes a Stock a Good Dividend Stock?
- An inside day for Target says another sell-off looms
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.